Exenatide once weekly meets endpoint

Amylin (NASDAQ:AMLN), Alkermes (NASDAQ:ALKS) and Eli Lilly (NYSE:LLY) said top-line data showed that exenatide once weekly met the primary endpoint in the Phase IIIb DURATION-2 trial in 491 patients with Type II diabetes. In the double-blind, international study, exenatide once weekly significantly reduced HbA1c from baseline vs. Januvia sitagliptin from Merck (NYSE:MRK) and Actos pioglitazone from Takeda (Tokyo:4502) at 26 weeks (1.7% vs. 1% and 1.4% reductions, respectively). Patients entered the trial with average HbA1c levels of 8.5%. ...